July 22, 2014 — IBA (Ion Beam Applications SA) announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for its compact gantry beam line. IBA anticipates this regulatory approval will intensify the international interest in ProteusONE, IBA’s next-generation proton therapy compact system.
ProteusONE is IBA’s single-room proton therapy system that is smaller, less expensive, faster to install and encompasses the latest in targeted proton therapy technologies, including intensity-modulated proton therapy (IMPT). IBA created the ProteusONE system to allow more patients access to proton therapy globally and has already sold five systems in Shreveport, La.; Nice, France; Taiwan; and two in Japan.
“We are delighted to have received marketing authorization from the FDA for the ProteusONE compact gantry. This is an exciting milestone for our customers in North America, where the cost of healthcare is a major focus. The ProteusONE aligns with the U.S. healthcare trend of providing the highest quality of cancer treatment possible at the best possible price,” said Olivier Legrain, CEO of IBA. “We are confident that ProteusONE will drive greater momentum in the adoption of this next-generation targeted cancer treatment internationally. The approval reaffirms our world-leading position in the delivery of highly targeted, safer cancer treatment solutions. We very much look forward to the first patients at the Willis-Knighton Cancer Center [in Shreveport] benefitting from our compact proton therapy offering later this year.”
Added Lane R. Rosen, M.D., director of radiation oncology at the Willis-Knighton Cancer Centre: “We are very excited to have IMPT become an available option for our patients. The complete clearance of the ProteusONE system, installed at Willis-Knighton, is yet another milestone demonstrating how IBA and WKCC partner for progress.”
ProteusONE is the brand name of a new configuration of the Proteus 235.
For more information: www.iba-worldwide.com
March 28, 2024 
